Antagonists of IL-6 to prevent or treat thrombosis
View Patent ↗The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
1. A method of reducing the risk of hypercoagulation or thrombosis in a subject having an elevated IL-6 level and an elevated D-dimer level by reducing the level of serum D-dimer in said subject, comprising administering to the subject an amount of an IL-6 antagonist, wherein said IL-6 antagonist is an antibody or antibody fragment that specifically binds human IL-6, wherein said antibody or antibody fragment comprises a variable light (VL) region containing the VL complementarity regions, CDR1, CDR2 and CDR3, respectively in SEQ ID NO:4, 5 and 6, and comprises a variable heavy (VH) region containing the VH complementarity regions, CDR1, CDR2 and CDR3, respectively in SEQ ID NO:7, 8 or 120 and 9, and which antibody or fragment is administered in an amount effective to reduce the level amount of serum D-dimer thereby reducing the risk of hypercoagulation or thrombosis in said subject.
2. The method of claim 1 , wherein the light chain comprises a polypeptide which is at least 90% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.
3. The method of claim 1 , wherein the heavy chain comprises a polypeptide which is at least 90% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.
4. The method of claim 1 , wherein the light chain comprises a polypeptide which is at least 95% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.
5. The method of claim 1 , wherein the heavy chain comprises polypeptide which is at least 95% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.
6. The method of claim 1 , wherein the light chain comprises polypeptide which is at least 98% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.
7. The method of claim 1 , wherein the heavy chain comprises a polypeptide which is at least 98% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.
8. The method of claim 1 , wherein the light chain comprises a polypeptide which is at least 99% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.
9. The method of claim 1 , wherein the heavy chain comprises a polypeptide which is at least 99% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.
10. The method of claim 1 , wherein the light chain comprises a polypeptide which is identical to the light chain framework region having the sequence contained in SEQ ID NO:699.
11. The method of claim 1 , wherein the heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.
12. The method of claim 1 , wherein the light chain comprises a polypeptide which is identical to the light chain framework region having the sequence contained in SEQ ID NO:2 or 20.
13. The method of claim 1 , wherein the heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence contained in SEQ ID NO:3, 18 or 19.
14. The method of claim 1 , wherein the light chain comprises a polypeptide which is identical to the light chain framework region having the sequence contained in SEQ ID NO: 20 and he heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence contained in SEQ ID NO: 18 or 19.
15. The method of claim 1 wherein the antibody or fragment comprises human IgG1 constant regions.
16. The method of claim 14 wherein the antibody or fragment comprises human IgG1 constant regions.
17. The method of claim 1 wherein the D-dimer levels are determined before antibody administration.
18. The method of claim 1 wherein said subject also has an elevated C-reactive protein (CRP) level prior to treatment.
19. The method of claim 1 wherein said method further comprises the administration of at least one statin or anti-coagulant.
20. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the subject with a frequency at most once per period of approximately four weeks.
21. The method of claim 1 , wherein the subject's coagulation profile is assayed after treatment.
22. The method of claim 1 , wherein the subject's coagulation profile is assayed before treatment.
23. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment has an elimination half-life of at least about 22 days.
24. The method of claim 1 , further comprising administration of one or more anti-coagulants or statins.
25. The method of claim 1 , wherein the subject's coagulation profile is assessed before or after treatment by measurement of the subject's serum level of one or more of D-dimer, Factor II, Factor V, Factor VIII, Factor IX, Factor XI, Factor XII, F/fibrin degradation products, thrombin-antithrombin III complex, fibrinogen, plasminogen, prothrombin, and von Willebrand factor.
26. The method of claim 1 , further comprising measuring the subject's international normalized ratio (INR) prior to administration of the anti-IL-6 antibody or antibody fragment and administering to the subject said anti-IL-6 antibody if the subject's INR is less than about 0.9.
27. The method of claim 1 , wherein the subject's serum D-dimer level is lowered to less than the upper limit of the normal reference range within 4 weeks of administering to the subject said anti-IL-6 antibody.
28. The method of claim 1 , wherein the subject treated has cancer.
29. The method of claim 1 , wherein the subject being treated is undergoing chemotherapy.
30. The method of claim 1 , further comprising measuring the level of IL-6 in the subject prior to treatment.
31. The method of claim 1 , further comprising measuring the level of C-reactive protein in the subject prior to treatment.
32. The method of claim 21 , wherein the subject's coagulation profile is assayed by a method comprising measuring the concentration of D-dimer in the subject's serum.
33. The method of claim 22 , wherein the subject's coagulation profile is assayed by a method comprising measuring the concentration of D-dimer in the subject's serum.
34. The method of claim 1 , wherein said antibody or fragment inhibits the interaction of IL-6 with gp130.
35. The method of claim 1 , wherein said antibody or fragment inhibits the interaction of IL-6 with IL-R 1.
36. The method of claim 1 , wherein said antibody or fragment inhibits the interaction of IL-6 with gp 130 and IL-6R1.
37. The method of claim 1 , wherein said antibody or fragment neutralizes IL-6 in vivo.
38. The method of claim 14 , wherein said antibody or fragment neutralizes IL-6 in vivo.
39. The method of claim 1 , wherein said antibody or fragment binds to IL-6 with a dissociation constant (K D ) of less than or equal to 5×10 −7 , 10 −7 , 5×10 −8 , 10 −8 , 5×10 −9 , 10 −9 , 5×10 −10 , 10 −10 , 5×10 −11 , 10 −11 , 5×10 −12 , 10 −12 , 5×10 −13 , 10 −13 , 5×10 −14 , 10 −14 , 5×10 −15 or 10 −15 .
40. The method of claim 1 , wherein said antibody or fragment binds to IL-6 with a dissociation constant of less than or equal to 5×10 −10 .
41. The method of claim 1 , wherein said antibody or fragment possesses a binding affinity (Kd) less than 50 picomolar.
42. The method of claim 1 , wherein said antibody or fragment possesses a K off value less than or equal to 10 −4 S −1 .
43. The method of claim 1 , wherein said antibody or fragment is administered intravenously.
44. The method of claim 14 , wherein said antibody or fragment is administered intravenously.
45. The method of claim 1 , wherein said antibody or fragment is administered subcutaneously.
46. The method of claim 14 , wherein said antibody or fragment is administered subcutaneously.